P. Ekert

Precision-guided treatment in high-risk pediatric cancers
202446 citationsauthor #42
Functional precision medicine for pediatric cancers
20245 citationsauthor #2
Author Correction: Functional precision medicine for pediatric cancers
20241 citationsauthor #2
Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing
202410 citationsauthor #13
A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax
20244 citationsauthor #17
Harnessing immune checkpoint trial data in pediatric cancer
20230 citationsauthor #2
SYST-15 GENERATION AND MULTI-DIMENSIONAL PROFILING OF A CHILDHOOD CANCER CELL LINE ATLAS DEFINES NEW THERAPEUTIC OPPORTUNITIES
20230 citationsauthor #34
Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas
20230 citationsauthor #31
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer
202324 citationsauthor #33
Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
20238 citationsauthor #21
TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
202377 citationsauthor #26
Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.
202341 citationsauthor #40
TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data
20237 citationsauthor #6
Molecular principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision
20231 citationsauthor #10
Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes
202315 citationsauthor #19
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
202321 citationsauthor #2
In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma
20234 citationsauthor #19
Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL
202311 citationsauthor #16
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
202233 citationsauthor #18
De novo design of CRISPR-Cas13b enables efficient silencing of SARS-CoV-2 variants and tumour pathogenic RNAs with near single-base precision
20220 citationsauthor #15
SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia
202211 citationsauthor #16
A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer
20226 citationsauthor #44
Toblerone: detecting exon deletion events in cancer using RNA-seq
20223 citationsauthor #5
Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions.
20228 citationsauthor #11
Advances in CAR T cell immunotherapy for paediatric brain tumours
20227 citationsauthor #9
MODL-17. The Childhood Brain Cancer Cell Line Atlas: A Resource for Biomarker Identification and Therapeutic Development
20220 citationsauthor #27
Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions
20221 citationsauthor #11
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
202239 citationsauthor #17
ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia
202246 citationsauthor #9
ALLSorts: a RNA-Seq classifier for B-Cell Acute Lymphoblastic Leukemia
20213 citationsauthor #9
Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas.
202112 citationsauthor #2
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma
202119 citationsauthor #12
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
202134 citationsauthor #48
Abstract 639: Analysis of DNA minimal residual disease markers in pediatric solid cancers using quantitative real time PCR and droplet digital PCR
20210 citationsauthor #11
Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis
202119 citationsauthor #10
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
202131 citationsauthor #9
Early-phenotype CAR-T cells for the treatment of pediatric cancers.
202119 citationsauthor #6
Cycling without brakes lets ALL escape.
20210 citationsauthor #2
Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia
20211 citationsauthor #4
Matching target to therapy in childhood cancers
20210 citationsauthor #1
Slinker: Visualising novel splicing events in RNA-Seq data
20211 citationsauthor #3
Abstract 3044: The unexplored immune landscape of high-risk pediatric cancers
20210 citationsauthor #13
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma
202110 citationsauthor #13
JAFFAL: detecting fusion genes with long-read transcriptome sequencing
202159 citationsauthor #6
Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
20218 citationsauthor #8
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma
20211 citationsauthor #13
Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance
202057 citationsauthor #10
MINTIE: identifying novel structural and splice variants in transcriptomes using RNA-seq data
202022 citationsauthor #4
Abstract SY09-02: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia
20200 citationsauthor #3
Signalling in high-risk paediatric cancers – Genomic insights driving therapeutic possibilities
20200 citationsauthor #1
Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).
20203 citationsauthor #6
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia.
202076 citationsauthor #20
Immune profiling of pediatric solid tumors.
202037 citationsauthor #5
MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia.
20205 citationsauthor #10
Abstract A03: Prevalence and spectrum of germline mutations in children with high-risk cancer
20200 citationsauthor #4
Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies
20200 citationsauthor #50
A Novel Orthotopic Patient-Derived Xenograft Model of Radiation-Induced Glioma Following Medulloblastoma
20207 citationsauthor #17
Histone-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis
20200 citationsauthor #37
Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer
20202 citationsauthor #21
EARLY-PHENOTYPE LEWIS Y CAR-T CELLS PERSIST BETTER IN VIVO AND INDUCE SOLID TUMOR REGRESSION IN COMBINATION WITH ANTI-PD1
20200 citationsauthor #19
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
2020293 citationsauthor #59
DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM
20200 citationsauthor #7
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
20206 citationsauthor #48
Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
20200 citationsauthor #19
Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors
20207 citationsauthor #20
126 Early-phenotype Lewis Y CAR-T cells persist better in vivo and induce solid tumor regression in combination with anti-PD1
20202 citationsauthor #8
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.
202030 citationsauthor #23
Using equivalence classes for differential transcript usage and variant detection in RNA-seq data
20200 citationsauthor #3
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
2020127 citationsauthor #41
Development of next generation car's targeting the lewis y antigen for the treatment of cancer
20191 citationsauthor #6
THER-23. RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRATED PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS
20190 citationsauthor #36
Abstract 3111: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer
20191 citationsauthor #6
iPREDICT: Incorporating complex profiling of patients to enrol onto molecularly directed cancer therapeutics. Preliminary results of the adult and paediatric
20190 citationsauthor #6
ENHANCING EXPRESSION OF PRO-APOPTOTIC FACTORS THROUGH INHIBITION OF HDACS DRIVES P53-INDEPENDENT SYNERGY WITH VENETOCLAX FOR THE TREATMENT OF AML
20190 citationsauthor #10
Targeted therapy and disease monitoring in CNTRL‐FGFR1‐driven leukaemia
20198 citationsauthor #13
Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions
201947 citationsauthor #15
MicroRNA-155 expression and function in AML: An evolving paradigm.
201833 citationsauthor #3
Abstract LB-137: Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors
20180 citationsauthor #11
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
2018172 citationsauthor #45
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
2018172 citationsauthor #44
Different Classes of ABL1 Fusions Activate Different Downstream Signalling Nodes
20180 citationsauthor #11
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
2018141 citationsauthor #15
Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer
201821 citationsauthor #11
IDENTIFICATION OF POTENT BH3-MIMETIC COMBINATIONS TARGETING PRO-SURVIVAL PATHWAYS IN HUMAN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
20181 citationsauthor #14
Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML
20185 citationsauthor #9
Role of the beta Common (beta c) Family of Cytokines in Health and Disease
20186 citationsauthor #18
Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome
20180 citationsauthor #36
Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
2018479 citationsauthor #18
HoxA 9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA 9-dependent leukemia
20182 citationsauthor #16
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
20181 citationsauthor #18
Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
20183 citationsauthor #44
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
2018103 citationsauthor #18
EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA
20180 citationsauthor #8
Exploring the feasibility and utility of exome‐scale tumour sequencing in a clinical setting
201822 citationsauthor #11
Role of the β Common (βc) Family of Cytokines in Health and Disease.
201840 citationsauthor #18
Abstract LB-138: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer
20181 citationsauthor #6
Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
20183 citationsauthor #45
Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target
20181 citationsauthor #6
Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death
20177 citationsauthor #6
Genetic determinants of anthracycline cardiotoxicity – ready for the clinic?
201710 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT